Nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP) are important regulators of bile acid, lipid, and glucose homeostasis. Here, we show that global Fxr -/-Shp -/-double knockout (DKO) mice are refractory to weight gain, glucose intolerance, and hepatic steatosis when challenged with high-fat diet. DKO mice display an inherently increased capacity to burn fat and suppress de novo hepatic lipid synthesis. Moreover, DKO mice were also very active and that correlated well with the observed increase in phosphoenolpyruvate carboxykinase expression, type IA fibers, and mitochondrial function in skeletal muscle. Mechanistically, we demonstrate that liver-specific Shp deletion protects against fatty liver development by suppressing expression of peroxisome proliferator-activated receptor gamma 2 and lipid-droplet protein fatspecific protein 27 beta. Conclusion: These data suggest that Fxr and Shp inactivation may be beneficial to combat dietinduced obesity and uncover that hepatic SHP is necessary to promote fatty liver disease.
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O besity is a major epidemic with a prevalence of around 35% in adults, as estimated by the Centers of Disease Control and Prevention in the United States. Importantly, obese individuals have an increased risk for developing a variety of metabolic diseases, including fatty liver (hepatic steatosis; HS), abnormal lipid levels in the blood (dyslipidemia), and, most commonly, type 2 diabetes.
(1-3) Fat accumulation in the liver can promote insulin resistance (IR), (3, 4) which, in turn, results in increased morbidity and mortality rates. Thus, understanding the molecular machinery that causes fatty liver will provide insight into approaches that are amenable for therapeutic options.
Nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner (SHP), in addition to regulating bile acid levels, also control energy metabolism and glucose homeostasis. (5) (6) (7) (8) (9) (10) Several human single-nucleotide polymorphisms in the Fxr gene have been correlated with fasting hyperglycemia and free fatty acids (FAs), (6) whereas mutations in the Shp gene are associated with obesity (11, 12) and susceptibility to type 2 diabetes. (13) Global FxrKO mice are protected against diet-induced obesity; however, there is also evidence that FxrKO mice are glucose intolerant and insulin insensitive. (14) (15) (16) ShpKO mice do not exhibit obesity, but develop IR when challenged with Western diet (WD). (17) These results demonstrate that FXRand SHP-mediated control of glucose is multilayered.
In addition to glucose control, FXR and SHP are known to play a critical role in regulating cholesterol and lipid levels (18, 19) and thus can directly affect fat content in the liver. For instance, FXR through activation of Shp has been shown to suppress sterol regulatory element binding protein-1c (Srebp1-c), an important regulator of lipogenesis in the liver. (20) Thus, FXR and SHP are central for metabolic homeostasis because they not only regulate glucose levels, but also hepatic fat content. These two functions are subtly regulated to maintain a beneficial metabolic state. But when this balance is perturbed, it can trigger a vicious cycle whereby hepatic steatosis (HS) can cause IR, which, in turn, can promote more fat accumulation in the liver. (21) We previously discovered a synergistic role for FXR and SHP in controlling bile acid levels, (22) which led us to investigate whether these receptors cooperate to maintain energy balance and to carefully dissect their liverspecific contribution toward metabolic homeostasis.
Here, we show that combined loss of Fxr and Shp in mice (double knockout; DKO) results in reduced body weight gain and better glucose control, both under chow as well as high-fat diet (HFD) conditions. Furthermore, DKO mice displayed increase in fat burning capacity, mitochondrial function, and type IA fibers along with higher physical activity. This was substantiated by the observed increase in phosphoenolpyruvate carboxykinase (Pepck) and peroxisome proliferatoractivated receptor gamma (Pparc) transcript levels in DKO skeletal muscle compared to WT mice on HFD. Notably, DKO animals did not develop fatty liver when challenged with an HFD. Mechanistically, we found that FA synthesis and metabolism are downregulated in livers of DKO mice. Importantly, protection against HS upon high-fat feeding was recapitulated when Shp was specifically deleted in the liver (LShpKO). These findings indicate that antagonizing SHP may be beneficial to treat fatty liver.
Materials and Methods

ANIMALS
The generation of Fxr and Shp DKO mice has been described. (22) Mice were bred and maintained in a temperature-controlled (238C) facility on standard 12-hour light/dark cycles. Adult wild-type (WT) C57BL/6, DKO, FxrKO, ShpKO, Albumin-Cre, Flox/ Flox Fxr, Flox/Flox Shp, L-FxrKO, and L-ShpKO mice were used in this study. L-FxrKO and L-ShpKO mice were generated by breeding the respective homozygous floxed alleles with Albumin-Cre animals. At 8-10 weeks, mice were fed normal chow diet (11% fat) or 45% HFD from Harlan Teklad, Indianapolis, IN for 8 weeks to mimic obese conditions. Flox/Flox control and L-ShpKO mice were also challenged with control or Western diet (WD) from Harlan Teklad for 21 weeks. (23) Mice were sacrificed at the end of the experimental regimen. Liver, intestine, and skeletal muscle tissues were collected for biochemical studies, gene expression and histology. National Institutes of Health (NIH) guidelines for use and care of laboratory animals was followed, and all the experiments were approved by the Institutional Animal Care and Use Committee at the University of Illinois at Urbana-Champaign (Champaign, IL), Baylor College of Medicine (Houston, TX), and at Northeast Ohio Medical University (Rootstown, OH). Body fat composition was evaluated by dual-energy x-ray absorptiometry (DEXA).
Indirect calorimetry was performed using the Comprehensive Lab Animals Monitoring System (CLAMS; Oxymax; Columbus Instruments) as described. (24) Animals were acclimated to the CLAMS cages, and data were collected over the subsequent 72-hour period. Food intake and time spent to access food was recorded ad libitum. Feces were collected after 24 hours of acclimatization. Pair-fed mice were utilized to measure rate of oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), as well as ambulatory activity. Data were analyzed using Oxymax software (Columbus Instruments).
RNA ANALYSIS
Total RNA from mice livers were isolated using TRIzol (Invitrogen) reagent and prepared according to the manufacturer's instructions. Upon DNAse treatment (NEBioLabs), RNA (2 ug) was reverse transcribed using random primers and a Maxima reverse transcriptase kit (Thermo Scientific). Complementary DNA was diluted to 12.5 ng/uL, and 50 ng were used for each SYBR green-based qPCR reaction. The QPCR primers are provided in Supporting Table 1 .
SERUM CHEMISTRY
Blood was collected by retro-orbital bleeding from mice and centrifuged at 8,000g for 10 minutes. Serum triglycerides (TGs) and cholesterol were performed using Thermo Scientific Total cholesterol or triglyceride kits. Additionally, an Insulin ELISA kit (AbNova) was used to determine serum insulin levels. Serum glucose was measured using one-touch glucose strips.
GLUCOSE AND INSULIN TOLERANCE TESTS
The glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed as described. (17, 25) Briefly, mice were fasted overnight and injected with D-glucose at 2 g/kg intraperitoneally to perform the GTT. Blood glucose concentrations were measured at 0, 15, 30, 60, and 120 minutes after glucose injections. For the ITT, mice were fasted for 4 hours and injected intraperitoneally with insulin (Humulin; Eli Lilly) 1.0 U/kg body weight. Blood glucose concentrations were measured at 15, 30, 60, and 90 minutes after insulin injection.
HISTOLOGY AND IMAGING
Liver and skeletal muscle tissues were fixed in 10% neutral-buffered formalin or embedded in optimum cutting temperature (OCT) fixative and processed. Frozen sections were stained with either Oil Red O or succinate dehydrogenase (SDH) as described. (26) Paraffinembedded sections were used to perform hematoxylin and eosin (H&E) staining. After a 4-hour fast, mice were gavaged with BODIPY 500/510 and olive oil (10 lL/g body weight). Liver and intestines were excised and frozen in OCT medium 4 hours postgavage. Tenmicrometer sections were cut, mounted with Antifade reagent with 4 0 ,6-diamidino-2-phenylindole, and examined under a fluorescence microscope and quantitated using adiposoft in ImageJ (NIH, Bethesda, MD). (27) 
MITOCHONDRIAL ACTIVITY
Electron transport chain enzymes were assayed using a temperature-controlled spectrophotometer (Ultraspec 6300 pro; Biochrom Ltd., Cambridge, UK) as described. (28) All assays were performed in duplicates. Activities of complex I (nicotinamide adenine dinucleotide/ferricyanide reductase), complex II (SDH), and complex IV (cytochrome c oxidase) were measured. Citrate synthase (CS) was used as a marker for mitochondrial content. Enzyme activities are expressed in nmol/min/mg of protein.
STATISTICAL ANALYSIS
Data are expressed as mean 6 SEM, unless otherwise specified. Statistics were performed using GraphPad Prism 6 software. The Student t test was used to compare two groups and a one-way analysis of variance Bonferroni test for multiple group comparisons. Data are significant if P value 0.05, with *P 0.05, **P 0.01, ***P 0.001, and ****P 0.0001.
Results
Fxr, Shp DKO MICE ARE RESISTANT TO DIET-INDUCED OBESITY AND ARE PROTECTED AGAINST DEVELOPING HS
To determine whether there is a synergistic role for FXR and SHP in maintaining glucose and energy metabolism, we challenged Fxr and Shp DKO mice (22) with either a chow diet or an HFD. Compared to WT, DKO mice had a lower body weight even on the normal chow diet (Fig. 1A,B) . Despite the reduction in body weight, DKO mice exhibited an increase in lean mass with a striking reduction in total fat mass (Fig. 1C) . We next examined whether the difference in weight gain is attributed to alterations in food intake by CLAMS (Columbus Instruments). We found that DKO mice ate less than WT under the normal chow condition, but this reduction was lost when normalized to their respective body weights (Fig. 1D) . To evaluate the decrease in absolute value of food consumed in DKO mice, we examined serum leptin levels, which inhibit feeding, (29, 30) and found lower leptin levels in DKO mice, indicating that these mice did not have a suppressed appetite (data not shown). However, the basal glucose levels were lower, and upon glucose and insulin challenge, DKO animals displayed better glucose homeostasis and insulin sensitivity (Fig. 1E,F and Supporting Fig.  S1A ,B) than WT mice. DKO mice also showed inflammation and cytoplasmic swelling of hepatocytes along with no change in circulating TGs or cholesterol levels (Supporting Fig. S1C-E) . Furthermore, urine amount, fecal weight, and feces color of DKO mice were similar to that of WT mice. These data suggest that DKO mice may not excrete excess fat in their feces (Supporting Fig. S1F ). We conclude that in the absence of FXR and SHP animals have less body fat and better glucose homeostasis.
We next wanted to determine how mice responded when challenged with an HFD. DKO mice were resistant to gaining weight ( Fig. 2A) , had reduced fat mass (Fig. 2B ) despite similar food intake, did not develop insulin resistance, and maintained an excellent glucose tolerance (Fig. 2C-F and Supporting Fig. S2A ) compared to WT animals. Furthermore, HFD-fed DKO animals displayed similar circulating levels of insulin,TG, and cholesterol, except significantly reduced levels of hepatic TGs compared to HFD-fed WT mice (Supporting Fig. S2A-C) . We then questioned whether DKO mice had a defect in fat uptake in the gut. To address this, we oral gavaged BODIPY together with olive oil and analyzed the enterocytes with confocal microscopy. We found abundant labeled lipid droplets in both WT and DKO mice, indicating no defect in absorption except that DKO mice showed smaller droplet size (Supporting Fig. S2D,E) . (E,F) DKO mice are more glucose tolerant and insulin sensitive as determined by GTT and ITT (n > 9 per group). The Student t test was used to compare two groups. Mean 6 SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared to WT mice. Abbreviation: B.wt, body weight.
DKO MICE BURN MORE FAT AND EXHIBIT INCREASED ACTIVITY COMPARED TO WT MICE
We then examined whether energy expenditure and fat burning were contributing toward the lean metabolic phenotype in DKO mice by measuring VO 2 and VCO 2 (Fig. 3A,B) . Our analysis revealed that DKO mice have lower respiratory exchange rate (RER), both during the day and night, compared to WT mice, indicating preferential fat burning (Fig. 3C) . The timepoint line graphs clearly demonstrate that both WT and DKO mice exhibit increased carbohydrate burning during the night as they eat nocturnally (Supporting Fig. S3A-C) . Despite this shift, DKO mice maintain an overall lower RER throughout the day and night under HFD that is more pronounced under a normalchow-fed state (Supporting Fig. S3C) .
We next analyzed their physical activity and found that DKO mice displayed increased activity (Fig.  4A,C) . Because the DKO mice were more mobile and active, we examined whether the skeletal muscle was supporting efficient fat utilization. We carefully analyzed the mitochondrial respiratory chain complexes I through IV in the skeletal muscle and identified a significant increase in complex I activity along with the complementary increase in complex IV activity. Additionally, the Krebs cycle enzyme, CS, which indicates mitochondrial function, was also considerably upregulated in DKO mice (Fig. 4B) . These data clearly show enhanced mitochondrial function in the DKO skeletal muscle compared to WT mice. Substantiating these functional biochemical data, we also demonstrate that the mitochondria-rich type I slow-twitch myofibers were significantly increased in the quadriceps muscle of DKO mice (Supporting Fig. S4A,C) . Importantly, these high-oxidative-capacity type I fibers were more pronounced when challenged with HFD in DKO than WT mice (Supporting Fig. S4B,D) . Coherent with increased oxidative capacity, the muscles expressed high levels of b-oxidation gene carnitine palmitoyl transferase 1 (Cpt1), Pparc, and Pepck genes in DKO mice (Fig. 4D) . Previously, it has been shown that increase in skeletal muscle Pparc levels increases oxidative muscle fibers, (31) whereas increase in Pepck is associated with elevated citric acid cycle flux and a preference for FAs as a fuel source. (32) Similarly, up-regulation of muscle Cpt1 is directly linked with increased FA oxidation and improved insulin sensitivity. (33) Taken together, these results reveal that the skeletal muscle of DKO mice promotes enhanced fat usage in these animals. . DKO mice show robust glucose tolerance (E) and insulin sensitivity (F) when maintained on an HFD (n > 12/group). The Student t test was used to compare two groups. Mean 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to WT mice. Abbreviation: B.wt, body weight.
AKINROTIMI, RIESSEN, ET AL. HEPATOLOGY, December 2017
DKO MICE DO NOT DEVELOP FATTY LIVER, AND DELETION OF HEPATIC Fxr DOES NOT RECAPITULATE THIS EFFECT
We found that liver expression of a glucose-sensing and lipid metabolic gene, carbohydrate-responsive element-binding protein b (Chrebp-b), and a gluconeogenic gene, Pepck, were maintained lower when Fxr and Shp were deleted (Fig. 5A) . Interestingly, overexpression of Chrebp-b has been shown to promote HS and Pepck overexpression causes IR. (34, 35) Thus, hepatic Chrebp-b and Pepck expressions are consistent with the beneficial metabolic profile of DKO mice. Furthermore, Cpt-1, the rate-limiting enzyme for fatty acid b-oxidation, was up-regulated both in liver of chow-and HFD-fed DKO animals (Fig. 5B) . Also, we found that the master regulators of FA and TG synthetic machinery in the liver, Srebp1c, fatty acid synthase (Fasn), acetyl-CoA carboxylase 1 (Acc1), and diacylglycerol O-acyltransferase-2 (Dgat2), were significantly down-regulated in the absence of Fxr and Shp upon HFD (Fig. 5C) . Further histological analyses demonstrate an overall resistance to fat accumulation in the liver, even when fed with excess calories (Fig.  5D,E) . These data indicate that decreased de novo lipid synthesis, coupled with increased oxidation of fat, protects DKO livers from developing HS. Reduction in HS thus may contribute toward the beneficial glucose and insulin tolerance observed in these DKO animals.
It is known that FXR can regulate hepatic de novo lipogenesis and thus control TG content in the liver. (20) Therefore, to precisely determine the role for hepatic FXR in mediating the beneficial effects observed in the DKO model, we generated liverspecific FxrKO mice (L-FxrKO). In contrast to DKO mice, L-FxrKO animals gained weight, developed fatty liver, and became glucose intolerant on HFD similar to controls (Supporting Fig. S5A,B,D) . Our results reveal that L-FxrKO mice accumulated more cholesterol and TG levels in serum and that their liver TG content was comparable to that of f/f Fxr mice fed HFD (Supporting Fig. S5C ). The glucose intolerance observed in L-FxrKO mice is in line with published data. (15) At the molecular level, we were intrigued to find suppression of Chrebp-b, Srebp1c, and Fasn gene expression in livers of HFD-fed L-FxrKO compared to f/f Fxr mice (Supporting Fig. S5E,F) , but this down-regulation was not to the same extent of DKO mice (Fig. 5A,B) . Despite suppression of several de novo lipogenic genes, L-FxrKO mice exhibit accumulation of hepatic TGs and development of steatosis. Furthermore, the expression profile of Pepck, Cpt1, and Fsp27b, a crucial lipid droplet stability protein, were regulated similarly between L-FxrKO and WT mice (Supporting Fig. S5E,F) . This can potentially be attributed to the marginal decrease in FA oxidation and pronounced increase in lipid droplet stability, as measured by Cpt1 and Fsp27b, respectively. Taken together, these findings imply that deletion of hepatic FXR is not responsible for the protection against HS and glucose tolerance observed in DKO mice.
LIVER-SPECIFIC Shp DELETION IS SUFFICIENT TO PROTECT MICE FROM DEVELOPING HS
To determine whether liver Shp was responsible for the observed beneficial phenotype in DKO mice, we generated and characterized liver-specific ShpKO (LShpKO) mice (Supporting Fig. S6A ). These mice gained 25%-30% less weight, accumulated significantly lower levels of visceral fat, and showed lower cholesterol and hepatic TGs when challenged with the HFD (Fig. 6A,B) . Consequently, L-ShpKO mice exhibited better glucose tolerance (Fig. 6C) , with significantly decreased accumulation of hepatic fat (Fig. 6D ) compared to control f/f Shp mice. These beneficial effects on glucose and weight gain were restricted to only HFD or WD conditions and were comparable between the two genotypes in chow-fed conditions (Supporting Fig. S6B,C) . However, loss of Shp resulted in lower serum TGs and cholesterol, even under the chow-fed state (Supporting Fig. S6D ). Finally, we examined whether this protection against fatty liver was maintained under the WD condition comprising of increased cholesterol, high fat, and high sucrose content. In line with HFD data, L-ShpKO mice were also protected against WD-induced weight gain and HS (Supporting Fig. S7A-E) , highlighting the importance of liver Shp in regulating cholesterol and TG levels. We investigated further and found down-regulation of important lipogenic regulators Srebp1c, Pparc2, and lipid droplet protein Fsp27b, which corroborates well with the reduction in hepatic TGs level in L-ShpKO mice ( Fig. 6E and Supporting Fig. S7F ). It has been recently shown that Fsp27b not only promotes droplet stability, but also inhibits lipolysis. (36, 37) Importantly, increased expression of Fsp27b is sufficient to promote HS. (38) Furthermore, when Shp is deleted, nuclear corepressor, NcoR as well as hepatocyte nuclear factor 4 alpha are no longer repressed and thus are able to mediate suppression of Pparc2 and subsequently downregulate Fsp27b. (23, 39) Overall, these results provide a mechanistic insight by which hepatic SHP can direct fat accumulation in the liver (Fig. 6F) .
Discussion
There are several reports on the role for FXR and SHP in regulating glucose homeostasis. (7, 10, 40) In this study, we examined their combined metabolic role in maintaining energy homeostasis and found that DKO mice exhibit improved glucose handling, increased FA oxidation, and are protected against HS, a marker for IR. (3) This implied that reducing both FXR and SHP function may be beneficial to achieving energy homeostasis in chow and HFD conditions.
To identify the mechanisms underlying this positive effect, we systematically examined the energy intake and expenditure. We found that increased utilization of fat, rather than differences in food intake or lipid absorption, contributed to the observed metabolic effect in the DKO mice. The increased physical activity and enhanced mitochondrial capacity of DKO skeletal muscle support the premise that the muscle may actually contribute toward utilizing excess fat (Fig. 4) . Several studies have demonstrated that fiber-type distribution is directly correlated with glucose tolerance. (41) Histological analysis in adult DKO skeletal muscle revealed an increase in SDH-positive fibers, indicating increased mitochondrial competence. Consequently, we also found increases in genes responsible for fat metabolism and gluconeogenesis that prevent IR and protect against metabolic defects. (32, 42) Moreover, we found increased Ppar-c along with Pepck expression in DKO muscle, both of which have been previously shown to increase type I fibers and be protective against diet-induced IR. (31, 32) These data reveal an important role for the skeletal muscle in protecting DKO mice against diet-induced obesity.
One intriguing finding is the tissue-specific misregulation of Pepck leading to its decrease in the liver, but increase in the muscle (Figs. 4 and 5) . This dichotomy of tissue-specific Pepck levels, however, is consistent with the observed beneficial metabolic phenotype in DKO mice, given that hepatic Pepck overexpression causes IR (35) whereas muscle overexpression promotes insulin sensitivity. (32) Insulin signaling has been shown to down-regulate hepatic Pepck levels, (43) which is in line with increased insulin sensitivity observed in DKO mice under both chow-and high-fat-fed conditions. However, transcriptional regulation of Pepck expression in skeletal muscle expression remains to be determined. Apart from the skeletal muscle, the liver expression profile of glucose and FA metabolic genes of DKO animals also demonstrate a favorable pattern of expression (Fig. 5) . For instance, the lack of lipid accumulation in the liver appears to be a direct effect of decreased lipogenesis coupled with increased fatty acid b-oxidation. Given that DKO mice are global knockouts, in order to tease apart the individual contribution of FXR and SHP to the observed beneficial phenotype, we generated liver-specific FxrKO as well as liverspecific ShpKO (Supporting Figs. S5 and S6 ). Our data show that deletion of hepatic Fxr did not protect mice against diet-induced steatosis and these findings are in line with earlier studies, which also revealed little role for liver Fxr in ameliorating diabetes subsequent to obesity. (15) However, intestinal Fxr agonism and antagonism have been implicated in protecting against obesity by two separate mechanisms. (44, 45) Therefore, intestinal Fxr, rather than hepatic Fxr, seems to be crucial in regulating metabolic outcome during obesity.
Next, we analyzed liver-specific ShpKO mice and found that loss of Shp in the liver contributes to the protection against HS and glucose tolerance phenotype when challenged with HFD. The protection against accumulation of hepatic TGs was dramatic and was maintained under both HFD and WD conditions, thus underscoring the importance of SHP in regulating this process. Importantly, these data are substantiated by the previous finding, which showed that Shp overexpression was sufficient to promote development of fatty liver in mice. (40) We found that despite calorie excess, L-ShpKO mice were not able to promote hepatic de novo lipogenesis to the extent of control mice. This was apparent because Srebp1c and Pparc2 levels were significantly lower in L-ShpKO mice. In addition Fsp27b, which is necessary for lipid droplet growth and fat storage, (46) was also robustly downregulated in the absence of Shp. Furthermore, it has been recently shown that Fsp27b is sufficient to cause fat accumulation in the liver. (37) SHP deletion thus effectively combats HS by reducing lipid synthesis as well as lipid droplet stability (Fig. 6) .
Last, because we know that DKO mice accumulate high bile acid levels, (22) we assessed whether the beneficial metabolic effects are secondary to the observed increase in bile acids. Thyroid hormone activation has been implicated in mediating the ability of bile acids to burn fat. (47) Therefore, we analyzed thyroid levels in DKO mice, but did not find activation or increase in thyroid levels in these animals (Supporting Fig. S8 ). However, it was recently shown that both increase, (48) as well as decrease, in bile acid pool was found to be protective against metabolic dysfunction subsequent to obesity. (49) These conflicting findings reveal that bile composition, rather than the total pool, may be crucial to regulating metabolic homeostasis. Importantly, if bile acids were contributing to the DKO phenotype, then they would have to be functioning independently of the FXR-SHP axis. Some of the beneficial effects, such as effective glucose homeostasis, could be achieved by activating Takeda G-protein-coupled receptor-5. (50) However, we know from our analysis of the individual L-FxrKO and L-ShpKO that the deletion of SHP is sufficient to protect against steatosis. This effect is bile acid independent because L-ShpKO mice do not have elevated hepatic bile acid levels (data not shown). These findings demonstrate that SHP regulates TG levels in the liver independent of FXR (Fig. 6E) .
As discussed earlier, the profound metabolic protection of DKO mice may be attributed to a combinatorial effect of elevated bile acids, intestinal deletion of Fxr, along with liver-specific deletion of Shp. The individual tissue-specific knockout studies have allowed us to disentangle the complexities and precisely identify the beneficial effects. Based on this study, we know that strong protection against HFD-induced steatosis can be achieved by inhibiting hepatic SHP levels. Given that SHP is required for both lipogenesis and to maintain intact lipid droplets, thus inhibiting hepatic SHP levels could be a potential therapeutic modality to treat fatty liver disease.
